Sentence examples for on clinical development from inspiring English sources

For example, Roche has four companies in the Hong Kong area, representing their pharmaceuticals and diagnostics businesses and focusing on clinical development of drugs and diagnostics that have already been developed and approved in other countries.

Frost & Sullivan reckons that in 2004 this market was worth $1.2 billion, with a further $1.6 billion spent on clinical development (testing on patients and so on).The big drugs firms have for years been outsourcing some or all of their clinical-development work to specialised research firms, such as Quintiles.

Given the growing number of vaccines in clinical trials, the rapid pace at which they are being tested, and the likelihood that an RSV vaccine will reach the commercial market in the next 5 10 years, consensus and guidance on clinical development pathways and licensure routes are needed now, before large-scale efficacy trials commence.

An analysis by Knowledge Ecology International shows that it is doubtful that Amgen spend more than $400 million on clinical development of the drug before approval, and that more than half of the early Phase I and II clinical trials on this drug were funded by the government through NIH or by universities.

Thus, it is likely that the increased serum levels of IL-10 in estradiol-treated mice contribute to the protective effect of estradiol on clinical development of arthritis as well as on systemic bone loss.

Comprehensive reviews were recently published on targeting the CTLA-4 receptor as a strategy for melanoma treatment [ 45, 46], and on clinical development of ipilimumab [ 47] and tremelimumab [ 48].

To our knowledge no p110α-selective inhibitor has gone on to clinical development.

5 9 In broad terms, drug development begins with discovery and preclinical laboratory research, before moving on to clinical development, starting with first testing in humans (phase I clinical trials) and continuing until regulatory review and approval.

Here, the tight control of the whole experimental setup is needed due to a possible impact either on a patient's treatment or on the strategy for clinical development of immune-modulatory compounds.

Eventually, agents are selected for clinical development on the basis of these evaluations and the availability of an appropriate formulation (oral whenever possible) with minimal or no potential toxicity and low cost.

It was selected for clinical development on account of its markedly superior antitumour efficacy in vivo in preclinical studies, in a series of experimental models compared to other Vinca alkaloids (Kruczynski et al, 1998a; Hill et al, 1999).